Sinopia Biosciences Publishes Preclinical Study Supporting SB-0110 for Parkinson's Disease
Thursday, July 16, 2026
Sinopia Biosciences has published preclinical research in Science Translational Medicine highlighting a new approach to treating Parkinson's disease. The study supports the development of SB-0110, the company's investigational therapy designed to improve the effectiveness of levodopa while reducing levodopa-induced dyskinesia (LID).
The research describes how selective positive modulation of PKA-II, a signalling protein located downstream of dopamine receptors, may improve the benefits of levodopa treatment and reduce dyskinesia. Levodopa remains the standard treatment for Parkinson's disease, but long-term use often leads to motor fluctuations and LID. Current add-on therapies and surgical treatments may improve levodopa's effects but can also increase dyskinesia, while the only approved treatment for dyskinesia has limited use because of side effects.
The publication marks an important milestone for Sinopia Biosciences by supporting its approach to addressing one of the major treatment challenges in Parkinson's disease. The findings also support the continued development of SB-0110, which is currently undergoing late-stage preclinical toxicology studies and is expected to enter clinical development in 2027.
The study used an omics-guided drug discovery approach to compare large-scale transcriptomic data with genetic signatures linked to both the therapeutic and adverse effects of levodopa. This process identified SB-0107, a positive PKA-II modulator with previous clinical experience in humans, as a potential treatment for Parkinson's disease.
In non-human primate models of Parkinson's disease with established dyskinesia, SB-0107 and its optimised derivatives, including SB-0110, significantly reduced dyskinesia while enhancing the anti-parkinsonian effects of levodopa.
Preclinical testing also showed that SB-0110 and SB-0107 had no meaningful activity across established Parkinson's disease drug targets, a broad range of GPCR targets, or an off-target safety panel. These findings indicate a distinct mechanism of action and support a favourable preclinical safety profile before investigational new drug (IND)-enabling toxicology studies.
The research also strengthens the case for omics-guided drug discovery as a method for identifying new therapeutic targets and drug candidates by analysing broad cellular changes rather than focusing on selected biological pathways.
The study received funding from the National Institute of Neurological Disorders and Stroke, the Michael J. Fox Foundation for Parkinson's Research, and the National Institute of General Medical Sciences. The published research was supported through grants from the US National Institutes of Health, although the findings and conclusions are the responsibility of the study authors and do not necessarily reflect the views of the funding organisations.
Source: globenewswire.com/
